CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

NCT04702841 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

CAR
Malignant Tumors

Interventions

DRUG: Chimeric antigen receptor modified γδ T cells

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]